collaborations

Jan 21, 2016

DelveInsight, the leading market research and consulting company has added new report    “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016”to its portfolio. Reports Highlights: ·      CAR-T cell Therapy Pipeline scenario ·      Collaborations &...

Jan 12, 2016

DelveInsight, the leading market research and consulting company has added new report   Pancreatic Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date i...

Jan 12, 2016

DelveInsight, the leading market research and consulting company has added new report Peripheral Lung Cancer-Pipeline Insights, 2016 to its portfolio. With this launch Delveinsight now has 700+ Reports on Indication Pipeline Insight. In addition to this our research expertise provides our clients with up to date inf...

Jan 12, 2016

DelveInsight has established its strong presence in therapeutic areas and has launched Analytical Reports on indication, mechanism of actions, drugs, Global API Manufacturers and specialized Reports on Gene Therapy, Anticoagulants, PD-1 and PDL-1, CART and Antibody Drug conjugates. After tremendous success last yea...

Jul 29, 2015

DelveInsight, the leading market research and consulting company has added new report  Bile Duct Cancer (Cholangiocarcinoma) -Pipeline Insights, 2015 to its portfolio. With this launch DelveInsight now has 700+ Reports on Indication Pipeline Insight. In addition to this, our research expertise provides our clients w...

Jul 24, 2015

In current scenario chemotherapies and radiations are prominently used to cure cancer which results in adverse effects. Oral Mucositis is one such adverse effect that results in ulceration in the mouth due to high dosage of chemotherapy. The patients undergoing head and neck cancer chemotherapy are at a high risk of...

Jul 23, 2015

Cancer is one of the pioneer causes of obliteration. Although a lot of therapies are being developed in this area but still there is a high unmet need. Currently companies are getting inclined towards Immunotherapies which are target specific (monoclonal and conjugated antibodies) and effective. One such therapy are...

Jun 17, 2015

In the field of oncology, no other approach is as attentive as Immunotherapy. Renewed interest in immunotherapy has been driven by Chimeric Antigen Receptor (CAR) T-cell therapy. This emerging approach is (CAR) T-cell technology which is showing great promise in immunotherapy. There are 35+ products in pipeline and...

Mar 18, 2015

Launch of DelveInsight’s Antibody-Drug Conjugate Report DelveInsight’s Antibody-Drug Conjugate: Global Market and Pipeline Outlook, 2015, report provides the information across the ADCs drug value chain. The Report provides the marketed and pipeline scenario of the ADCs. The Report has covered the 264 Antibody-dr...

Jan 08, 2015

Only a hundred and fifty years have passed since Gregor Mendel’s discovery of simple Mendelian inheritance. In a remarkably short amount of time humans have achieved such impressive feats as sequencing the entire human genome and gaining understanding of the causes of most genetic disease. Now that researchers have ...